I think I'd give it a B-.
I'm glad they did not give up anything of significance for what they got.
In the Bullpen, the first thing that has to be noted is that several closers were traded for next to nothing and the Braves did not get any of them. Their LH relief acquisition is Venters, who is coming off 3 TJ surgeries and has not been anywhere near as dominant as he was before. It's not clear that he's even a dominant LOOGY. Brach is not having a great year and seems to be best suited for getting RH out at this point. While both may not be used purely as specialists, the Braves did not acquire a true high leverage reliever in a season where they were cheap.
Duvall is having a bad year and was a flawed power hitter when he was going right. But he's a solid defender and maybe his platoon with Ender will improve things. I have my doubts.
Gausman does achieve the goal of obtaining another veteran controllable starter. Where Archer would have slotted into the front end at great cost, Gausman would seem to slot into the backend at relatively little cost. So this is very much more of a depth and value play than an all in going for it play.
So overall, it was a very cautious deadline strategy or at least result for Anthopolous. He parts with almost nothing of value and gets a return of players who on paper incrementally improve the team. But the FO will be hoping they outperform in Atlanta what they've done for their former teams.
I think it's a passable effort.
However, they did not obtain an upgrade to Camargo, or a platoon mate for him. They did not remove Flaherty from their bench despite their having no need for his positional utility. They don't have a big LH bat off the bench. They did not get a dominant LOOGY, or a leverage reliever who is having a good year. And they did not make any acquisition of a star level player.